Concise review: Drug discovery in the age of the induced pluripotent stem cell

Stem Cells Translational Medicine

Volumn 3, Issue 4, 2014, Pages 500-509

  Ko, Huaising C ^a   Gelb, Bruce D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Drug discovery; Drug screening; High throughput screening methods; Induced pluripotent stem cells; Preclinical drug evaluation

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL) ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL) PIPERIDINE; 3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL) PYRIDAZINIUM BROMIDE; 6 CYANO 7 NITRO 2, 3 QUINOXALINEDIONE; ANACARDIC ACID; CHLORIDE; CISAPRIDE; DANTROLENE; DEXPRAMIPEXOLE; DIBENZOYLMETHANE DERIVATIVE; GENTAMICIN; ISOPRENALINE; KENPAULLONE; KINETIN; LOXAPINE; METOPROLOL; NADOLOL; NIFEDIPINE; NIMODIPINE; OLESOXIME; PINACIDIL; PINACIDIL MONOHYDRATE; PROPRANOLOL; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RANOLAZINE; ROSCOVITINE; SOMATOMEDIN C; SOTALOL; TETRODOTOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BRAIN; CARDIOTOXICITY; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HEART MUSCLE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLURIPOTENT STEM CELL; RETT SYNDROME; TERATOGENICITY; TOXICITY;

DRUG DISCOVERY; DRUG SCREENING; HIGH-THROUGHPUT SCREENING METHODS; INDUCED PLURIPOTENT STEM CELLS; PRECLINICAL DRUG EVALUATION;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS;

EID: 84897502442     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0162     Document Type: Article

References (77)

1. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
2. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-1920.
3. Gupta MK, Illich DJ, Gaarz A et al. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol 2010;10:98.
4. Swistowski A, Peng J, Liu Q et al. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. STEM CELLS 2010;28: 1893-1904.
5. Okita K, Yamakawa T, Matsumura Y et al. An efficient nonviral method to generate integration-free human induced pluripotent stem cells from cord blood and peripheral blood cells. STEM CELLS 2012;31:458-466.
6. Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324: 797-801.
7. Fusaki N, Ban H, Nishiyama A et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009;85:348-362.
8. Kaji K, Norrby K, Paca A et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458:771-775.
9. Weltner J, Anisimov A, Alitalo K et al. Induced pluripotent stem cell clones reprogrammed via recombinant adeno-associated virus-mediated transduction contain integrated vector sequences. J Virol 2012;86:4463-4467.
10. Miyoshi N, Ishii H, Nagano H et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011;8:633-638.
11. Anokye-Danso F, Trivedi CM, Juhr D et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011;8:376-388.
12. Nerbonne JM. Studying cardiac arrhythmias in the mouse-a reasonable model for probing mechanisms? Trends Cardiovasc Med 2004;14:83-93.
13. Klunk WE, Lopresti BJ, Ikonomovic MD et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-10606.
14. Lahti AL, Kujala VJ, Chapman H et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012;5:220-230.
15. Tanaka T, Takahashi K, Yamane M et al. Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood 2012;120:1299-1308.
16. Cherry ABC, Gagne KE, McLoughlin EM et al. Induced pluripotent stem cells with a mitochondrial DNA deletion. STEM CELLS 2013;31: 1287-1297.
17. Sepac A, Si-Tayeb K, Sedlic F et al. Comparison of cardiomyogenic potential among human ESC and iPSC lines. Cell Transplant 2012;21: 2523-2530.
18. Gherghiceanu M, Barad L, Novak A et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: Comparative ultrastructure. J Cell Mol Med 2011; 15:2539-2551.
19. Ananiev G, Williams EC, Li H et al. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS ONE 2011;6:e25255.
20. Farra N, Zhang W-B, Pasceri P et al. Rett syndrome induced pluripotent stem cellderived neurons reveal novel neurophysiological alterations. Mol Psychiatry 2012;17: 1261-1271.
21. Cheung AYL, Horvath LM, Grafodatskaya D et al. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet 2011;20:2103-2115.
22. Yagi T, Ito D, Okada Y et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet 2011;20: 4530-4539.
23. Shi Y, Kirwan P, Smith J et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med 2012;4:124ra29.
24. Brennand KJ, Simone A, Jou J et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473:221-225.
25. Yang J, Cai J, Zhang Y et al. Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome. J Biol Chem 2010;285:40303-40311.
26. Chamberlain SJ, Chen P-F, Ng KY et al. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc Natl Acad Sci USA 2010; 107:17668-17673.
27. Itzhaki I, Maizels L, Huber I et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-229.
28. Rashid ST, Corbineau S, Hannan N et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010;120:3127-3136.
29. Jung CB, Moretti A, Mederos, Schnitzler M et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 2012;4: 180-191.
30. Kobayashi S, Yano M, Uchinoumi H et al. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2 (R2474S/+) knock-in mouse model. Circ J 2010;74:2579-2584.
31. Yazawa M, Hsueh B, Jia X et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471:230-234.
32. Egawa N, Kitaoka S, Tsukita K et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012;4: 145ra104.
33. Schenone M, Dančík V, Wagner BK et al. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 2013;9:232-240.
34. Hamasaki M, Hashizume Y, Yamada Y et al. Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: Mechanisms of reprogramming and strategy for drug identification. STEM CELLS 2012;30:2437-2449.
35. Zhao WN, Cheng C, Theriault KM et al. A high-throughput screen for Wnt/b-catenin signaling pathway modulators in human iPSC-derived neural progenitors. J Biomol Screen 2012;17:1252-1263.
36. Lee G, Ramirez CN, Kim H et al. Largescale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 2012;30:1244-1248.
37. Ferri N, Siegl P, Corsini A et al. Drug attrition during pre-clinical and clinical development: Understanding and managing druginduced cardiotoxicity. Pharmacol Ther 2013; 138:470-484.
38. Guo L, Abrams RMC, Babiarz JE et al. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 2011; 123:281-289.
39. Liang P, Lan F, Lee AS et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013;127:1677-1691.
40. Sollano JA, Kirsch JM, Bala MV et al. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Clin Pharmacol Ther 2008;84:263-266.
41. Colleoni S, Galli C, Gaspar JA et al. Characterisation of a neural teratogenicity assay based on human ESCs differentiation following exposure to valproic acid. Curr Med Chem 2012; 19:6065-6071.
42. Mayshar Y, Yanuka O, Benvenisty N. Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells. J Cell Mol Med 2011;15:1393-1401.
43. Lee EJ, Kim E, Azeloglu EU et al. Engineered cardiac organoid chambers: Toward a functional biological model ventricle. Tissue Eng Part A 2008;14:215-225.
44. Serrao GW, Turnbull IC, Ancukiewicz D et al. Myocyte-depleted engineered cardiac tissues support therapeutic potential of mesenchymal stem cells. Tissue Eng Part A 2012;18: 1322-1333.
45. Hansen A, Eder A, Bönstrup M et al. Development of a drug screening platform based on engineered heart tissue. Circ Res 2010; 107:35-44.
46. Tulloch NL, Muskheli V, Razumova MV et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 2011;109:47-59.
47. Lancaster MA, Renner M, Martin C-A et al. Cerebral organoids model human brain development and microcephaly. Nature 2013; 501:373-379.
48. Wang T, Wu H, Li Y et al. Subtelomeric hotspots of aberrant 5-hydroxymethylcytosinemediated epigenetic modifications during reprogramming to pluripotency. Nat Cell Biol 2013;15: 700-711.
49. Hu BY, Weick JP, Yu J et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA 2010; 107:4335-4340.
50. Feng Q, Lu S-J, Klimanskaya I et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. STEM CELLS 2010; 28:704-712.
51. Lapillonne H, Kobari L, Mazurier C et al. Red blood cell generation from human induced pluripotent stem cells: Perspectives for transfusion medicine. Haematologica 2010;95:1651-1659.
52. Chin MH, Mason MJ, Xie W et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009;5:111-123.
53. Marchetto MCN, Yeo GW, Kainohana O et al. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS ONE 2009;4:e7076.
54. Gore A, Li Z, Fung H-L et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-67.
55. Tobin SC, Kim K. Generating pluripotent stem cells: Differential epigenetic changes during cellular reprogramming. FEBS Lett 2012; 586:2874-2881.
56. Laurent LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8:106-118.
57. Novak A, Barad L, Zeevi-Levin N et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to b-adrenergic stimulation. J Cell Mol Med 2012;16:468-482.
58. Sun N, Yazawa M, Liu J et al. Patientspecific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012;4:130ra47-130ra47.
59. Matsa E, Rajamohan D, Dick E et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32:952-962.
60. Paca SP, Portmann T, Voineagu I et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011;17:1657-1662.
61. Kondo T, Asai M, Tsukita K et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A-beta and differential drug responsiveness. Cell Stem Cell 2013;12:487-496.
62. Yang YM, Gupta SK, Kim KJ et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 2013; 12:713-726.
63. Lee G, Papapetrou EP, Kim H et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402-406.
64. Marchetto MCN, Carromeu C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143: 527-539.
65. Paulsen BDS, Maciel R de M, Galina A et al. Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. Cell Transplant 2012;21:1547-1559.
66. Ebert AD, Yu J, Rose FF et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2008;457:277-281.
67. Wang Y, Jiang Y, Liu S et al. Generation of induced pluripotent stem cells from human b-thalassemia fibroblast cells. Cell Res 2009; 19:1120-1123.
68. Panicker LM, Miller D, Park TS et al. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci USA 2012;109:18054-18059.
69. Zhang J, Lian Q, Zhu G et al. A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011;8:31-45.
70. Tulpule A, Kelley JM, Lensch MW et al. Pluripotent stem cell models of ShwachmanDiamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell 2013;12:727-736.
71. Hiramoto T, Ebihara Y, Mizoguchi Y et al. Wnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia patient-derived pluripotent stem cells. Proc Natl Acad Sci USA 2013;110: 3023-3028.
72. Zhang S, Chen S, Li W et al. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet 2011;20:3176-3187.
73. Jonsson MKB, Wang Q-D, Becker B. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay Drug Dev Technol 2011;9:589-599.
74. Rana P, Anson B, Engle S et al. Characterization of human-induced pluripotent stem cellderived cardiomyocytes: Bioenergetics and utilization in safety screening. Toxicol Sci 2012; 130:117-131.
75. Tanaka T, Tohyama S, Murata M et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 2009;385:497-502.
76. Yang S-L, Harnish E, Leeuw T et al. Compound screening platform using human induced pluripotent stem cells to identify small molecules that promote chondrogenesis. Protein Cell 2012;3:934-942.
77. Yahata N, Asai M, Kitaoka S et al. Anti-Ab drug screening platform using human iPS cellderived neurons for the treatment of Alzheimer's disease. PLOS One 2011;6:e25788.